Laboratory Co. of America (NYSE:LH – Get Free Report) had its price target hoisted by investment analysts at Barclays from $213.00 to $249.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 6.54% from the company’s current price.
Several other research analysts have also recently weighed in on LH. Robert W. Baird raised their target price on Laboratory Co. of America from $261.00 to $277.00 and gave the company an “outperform” rating in a research note on Friday. JPMorgan Chase & Co. reduced their price objective on Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Truist Financial boosted their target price on Laboratory Co. of America from $255.00 to $275.00 and gave the stock a “buy” rating in a research report on Friday. Evercore ISI upped their target price on Laboratory Co. of America from $210.00 to $215.00 and gave the company an “in-line” rating in a report on Tuesday, July 9th. Finally, StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.43.
Get Our Latest Report on Laboratory Co. of America
Laboratory Co. of America Price Performance
Laboratory Co. of America (NYSE:LH – Get Free Report) last announced its earnings results on Thursday, August 1st. The medical research company reported $3.94 EPS for the quarter, topping the consensus estimate of $3.78 by $0.16. The firm had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.42 earnings per share. On average, sell-side analysts expect that Laboratory Co. of America will post 14.84 earnings per share for the current year.
Insider Activity
In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $210.83, for a total value of $421,660.00. Following the transaction, the executive vice president now directly owns 5,637 shares of the company’s stock, valued at approximately $1,188,448.71. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.85% of the stock is currently owned by corporate insiders.
Institutional Trading of Laboratory Co. of America
Several large investors have recently added to or reduced their stakes in the business. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Laboratory Co. of America in the 2nd quarter valued at $27,000. Pathway Financial Advisers LLC acquired a new stake in shares of Laboratory Co. of America in the first quarter worth about $30,000. Innealta Capital LLC acquired a new stake in shares of Laboratory Co. of America in the second quarter worth about $32,000. Family Firm Inc. bought a new stake in shares of Laboratory Co. of America during the 2nd quarter worth about $37,000. Finally, McClarren Financial Advisors Inc. increased its holdings in shares of Laboratory Co. of America by 313.2% during the 1st quarter. McClarren Financial Advisors Inc. now owns 219 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 166 shares during the last quarter. 95.94% of the stock is owned by institutional investors.
Laboratory Co. of America Company Profile
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).
Featured Articles
- Five stocks we like better than Laboratory Co. of America
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- Comparing and Trading High PE Ratio Stocks
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
- 3 Fintech Stocks With Good 2021 Prospects
- Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.